rolipram has been researched along with Endomyocardial Fibrosis in 1 studies
Endomyocardial Fibrosis: A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalk, P | 1 |
| Eggert, B | 1 |
| Relle, K | 1 |
| Godes, M | 1 |
| Heiden, S | 1 |
| Sharkovska, Y | 1 |
| Fischer, Y | 1 |
| Ziegler, D | 1 |
| Bielenberg, GW | 1 |
| Hocher, B | 1 |
1 other study available for rolipram and Endomyocardial Fibrosis
| Article | Year |
|---|---|
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Alanine Transaminase; Animals; Aspartate Aminotransfer | 2007 |